Member Login
Home » Money Talk Podcast Archives » Should You Join In The Frenzy For Big Pharma?

Should You Join In The Frenzy For Big Pharma?

Owain Bennallack is joined by Nate Weisshaar and Nathan Parmelee.

Posted by
Owain Bennallack
Owain is a magpie of the investing world -- and not because he gets into a flap. Almost any style of investing might suit him, depending on the bigger picture, and he's held all sorts of companies. Paraphrasing Keynes, he says: “When the market changes, I change my mind -- what do you do?” That said, Owain is usually a buyer of equities, where he prefers lightly geared, modestly rated companies, and is increasingly on the lookout for Buffett-style intangible quality. He aspires to buy-and-hold: his best investment ideas are worth much more than he sold them for. Then again, his worst investment went bust due to management fraud!
Published

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Owain Bennallack and his fellow Fools Nathan Parmelee and Nate Weisshaar explore the mega-merger mania that has gripped the pharmaceutical sector. Do these big deals make sense for shareholders, and what should you be doing? They also bash bankers’ outrageous bonuses and weigh up the pros and cons of AIM shares, before concluding as usual with three shares worth watching.​

Are you looking to profit from this uncertain economy? “10 Steps To Making A Million In The Market“ is the Motley Fool’s FREE guide to help Britain invest — better. We urge you to read the report today while it remains available. Just click here now!

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Money Talk Podcast Archives

Money Talk Podcast Archives

What You Should Really Worry About

| Owain Bennallack

Owain, Mark and Nate debate whether terrible events in far-flung countries are really likely to impact your investments.

Read more »

Money Talk Podcast Archives

Sex (Allegedly), Lies (Allegedly) And Videotape

| Owain Bennallack

The team discuss whether revelations about a covertly filmed sex tape really matter to Glaxo.

Read more »

Money Talk Podcast Archives

Investing In High-Growth Shares

| Owain Bennallack

Owain Bennallack is joined by US Fool Max Keeler to talk about high-growth disruptive companies.

Read more »

Money Talk Podcast Archives

Should You Buy Shares In TSB?

| Owain Bennallack

Owain Bennallack debates the pros and cons of investing in the TSB spin-off with Nate Weisshaar and Mark Rogers.

Read more »

Money Talk Podcast Archives

Time To Build A Position In The Housebuilders?

| Owain Bennallack

Owain and Nate discuss the housing bubble, IPOs, the state of the FTSE 100 (INDEXFTSE:UKX) as well as HSBC and…

Read more »

Money Talk Podcast Archives

Are Plunging Tech Shares A Buying Opportunity?

| Owain Bennallack

Owain, Mark and Nate discuss the tech share sell-off.

Read more »

Money Talk Podcast Archives

The Budget’s Big Breaks For Investors

| Owain Bennallack

Owain Bennallack dissects the fallout from this year's Budget with Nate Weisshaar and Mark Rogers.

Read more »

Money Talk Podcast Archives

Could World War 3 Curb Your Returns?

| Owain Bennallack

Owain Bennallack talks cheap Russian stocks with Nate Weisshaar and Mark Rogers.

Read more »